Opioids for chronic refractory breathlessness: Right patient, right route?

Drugs

Volumn 74, Issue 1, 2014, Pages 1-6

  Currow, David C ^a,d   Ekstrom, Magnus ^b   Abernethy, Amy P ^a,c  

^a FLINDERS UNIVERSITY   (Australia)

^b LUND UNIVERSITY   (Sweden)

^c DUKE UNIVERSITY   (United States)

^d REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDORPHIN; MORPHINE; MU OPIATE RECEPTOR AGONIST; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; NARCOTIC ANALGESIC AGENT;

CHRONIC REFRACTORY BREATHLESSNESS; DRUG SAFETY; DYSPNEA; HUMAN; IN VIVO STUDY; PALLIATIVE THERAPY; PROGNOSIS; RESPIRATION DEPRESSION; RESPIRATORY DISTRESS; REVIEW; STEADY STATE; UNPLEASANT SENSATION; BREATH ANALYSIS; CHRONIC DISEASE;

ANALGESICS, OPIOID; BREATH TESTS; CHRONIC DISEASE; DYSPNEA; HUMANS;

EID: 84893047491     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0162-8     Document Type: Review

References (52)

1. Pratter MR, Abouzgheib W, Akers S, et al. An algorithmic approach to chronic dyspnea. Respir Med. 2011;105(7):1014-21.
2. Currow DC, Plummer JL, Crockett A, et al. A community population survey of prevalence and severity of dyspnea in adults. J Pain Symptom Manage. 2009;38(4):533-45.
3. Currow D, Smith J, Davidson P, et al. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage. 2010;39(4):680-90.
4. Hammond EC. Some preliminary findings on physical complaints from a prospective study of 1,064,004 men and women. Am J Public Health Nations Health. 1964;54:11-23.
5. Frostad A, Soyseth V, Haldorsen T, et al. Respiratory symptoms and 30 year mortality from obstructive lung disease and pneumonia. Thorax. 2006;61(11):951-6.
6. Gift AG, Plaut SM, Jacox A. Psychologic and physiologic factors related to dyspnea in subjects with chronic obstructive pulmonary disease. Heart Lung. 1986;15(6):595-601.
7. Hui D, Morgado M, Vidal M, et al. Dyspnea in hospitalized advanced cancer patients: subjective and physiologic correlates. J Palliat Med. 2013;16(3):274-80.
8. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435-52.
9. Banzett RB, Pedersen SH, Schwartzstein RM, et al. The affective dimension of laboratory dyspnea: air hunger is more unpleasant than work/effort. Am J Respir Crit Care Med. 2008;177(12):1384-90.
10. Wan L, Van Diest I, De Peuter S, et al. Repeated breathlessness experiences induced by hypercapnia: differential effects on intensity and unpleasantness. Chest. 2009;135(2):455-61.
11. von Leupoldt A, Dahme B. Differentiation between the sensory and affective dimension of dyspnea during resistive load breathing in normal subjects. Chest. 2005;128(5):3345-9.
12. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939-44.
13. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523-8.
14. Oxberry SG, Torgerson DJ, Bland JM, et al. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail. 2011;13(9):1006-12.
15. Mancini I, Body JJ. Assessment of dyspnea in advanced cancer patients. Support Care Cancer. 1999;7(4):229-32.
16. Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil Nurs Off J Assoc Rehabil Nurs. 1989;14(6):323-5.
17. Gift AG, Narsavage G. Validity of the numeric rating scale as a measure of dyspnea. Am J Crit Care. 1998;7(3):200-4.
18. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest. 1986;89(2):234-6.
19. Lush MT, Janson-Bjerklie S, Carrieri VK, et al. Dyspnea in the ventilator-assisted patient. Heart Lung. 1988;17(5):528-35.
20. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1557-65.
21. Fletcher CM. The clinical diagnosis of pulmonary emphysema; an experimental study. Proc R Soc Med. 1952;45(9):577-84.
22. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751-8.
23. Yorke J, Moosavi SH, Shuldham C, et al. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax. 2010;65(1):21-6.
24. Uronis HE, Shelby RA, Currow DC, et al. Assessment of the psychometric properties of an English version of the cancer dyspnea scale in people with advanced lung cancer. J Pain Symptom Manage. 2012;44(5):741-9.
25. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42(10):773-8.
26. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85 Suppl B:25-31 (discussion 3-7).
27. Johnson MJ, Bland JM, Oxberry SG, et al. Clinically important differences in the intensity of chronic refractory breathlessness. J Pain Symptom Manag. 2013;46(6):957-63.
28. Karras DJ, Sammon ME, Terregino CA, et al. Clinically meaningful changes in quantitative measures of asthma severity. Acad Emerg Med Off J Soc Acad Emerg Med. 2000;7(4):327-34.
29. Ander DS, Aisiku IP, Ratcliff JJ, et al. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful? Congest Heart Fail (Greenwich, Conn). 2004;10(4):188-91.
30. Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J. 2009;33(4):771-7.
31. Gourlay GK, Plummer J, Cherry DA, et al. A comparison of Kapanol (a new sustained-release morphine formulation), MST Continus, and morphine solution in cancer patients: pharmacokinetic aspects of morphine and morphine metabolites. Seventh World Pain Congress, 1994. p. 631-43.
32. Mahler DA. Understanding mechanisms and documenting plausibility of palliative interventions for dyspnea. Curr Opin Support Palliat Care. 2011;5(2):71-6.
33. Mahler DA, Gifford AH, Waterman LA, et al. Effect of increased blood levels of beta-endorphin on perception of breathlessness. Chest. 2013;143(5):1378-85.
34. Jensen D, Alsuhail A, Viola R, et al. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage. 2012;43(4):706-19.
35. Davenport PW, Vovk A. Cortical and subcortical central neural pathways in respiratory sensations. Respir Physiol Neurobiol. 2009;167(1):72-86.
36. von Leupoldt A, Sommer T, Kegat S, et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med. 2008;177(9):1026-32.
37. Evans KC, Banzett RB, Adams L, et al. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol. 2002;88(3):1500-11.
38. Mahler DA. Opioids for refractory dyspnea. Expert Rev Respir Med. 2013;7(2):123-35.
39. Bellofiore S, Di Maria GU, Privitera S, et al. Endogenous opioids modulate the increase in ventilatory output and dyspnea during severe acute bronchoconstriction. Am Rev Respir Dis. 1990;142(4):812-6.
40. Gifford AH, Mahler DA, Waterman LA, et al. Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD. 2011;8(3):160-6.
41. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manag. 2011;42(3):388-99.
42. Ben-Aharon I, Gafter-Gvili A, Leibovici L, et al. Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis. Acta Oncol. 2012;51(8):996-1008.
43. Oxberry SG, Bland JM, Clark AL, et al. Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough. J Palliat Med. 2013;16(3):250-5.
44. Currow DC, Quinn S, Greene A, et al. The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea. J Palliat Med. 2013;16(8):881-6.
45. Johnson MJ, Bland JM, Oxberry SG, et al. Opioids for chronic refractory breathlessness: patient predictors of beneficial response. Eur Respir J. 2013;42(3):758-66.
46. Rocker G, Horton R, Currow D, et al. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax. 2009;64(10):910-5.
47. Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med. 2008;11(2):204-16.
48. Johnson MJ, Abernethy AP, Currow DC. The evidence base for oxygen for chronic refractory breathlessness: issues, gaps, and a future work plan. J Pain Symptom Manag. 45(4):763-75.
49. Krajnik M, Schafer M, Sobanski P, et al. Local pulmonary opioid network in patients with lung cancer: a putative modulator of respiratory function. Pharmacol Rep. 2010;62(1):139-49.
50. Shohrati M, Ghanei M, Harandi AA, et al. Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study. Pulm Med. 2012;2012:610921.
51. Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010;137(3):674-91.
52. Marciniuk DD, Goodridge D, Hernandez P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18(2):69-78.